Table 2. Recruiting clinical trials of tofacitinib in JIA patients.

JIA: Juvenile idiopathic arthritis.

Study Title	Proposed Study Population	Outcomes
A long-term, open-label follow-up study of tofacitinib for treatment for juvenile idiopathic arthritis (JIA)	Pediatric patients with JIA, aged 2 to under 18 years, who have completed a previous study on tofacitinib in patients with JIA.	Adverse events, safety, body weight, height and tanner stages will all be recorded for the duration of the study, up to 8 years. In addition, there are various secondary measurements outlined.
Efficacy, safety, tolerability and pharmacokinetics of tofacitinib for the treatments of systemic juvenile idiopathic arthritis (sJIA) with active systemic features in children and adolescent subjects	Pediatric patients from 2 to 17 years who have not been previously treated with tofacitinib for JIA and are on a stable dose of either methotrexate or oral prednisone.	The study plans to measure the time to flare-up for up to 82 weeks after randomization.